Rapport Therapeutics, Inc. (RAPP)
Develops experimental brain drugs to treat epilepsy, chronic pain, and other neurological disorders.
$41.96-0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+196.5%
The outlook
RAPP is trading near the top of its 52-week range, well above its long-term moving averages, with strong analyst consensus backing the stock. The average analyst price target sits roughly 40% above the current price, and the overall technical setup registers as bullish. Coverage is solid at 12 analysts, all leaning positive on the name.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 12 analysts
Price trendAbove its 50- & 200-day averages
52-week range92% of the way from its 52-week low to high
Price targetAvg target +40% vs current price
Analyst price target
~12-month · 12 analysts$58.59average target+39.6% vs now
Now $41.96
Low $40.00High $80.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.01B
52-wk high
$44.28
52-wk low
$13.62
50-day avg
$38.83
200-day avg
$31.81
Trailing P/E
—